RECOMBINANT STRAIN VV-GMCSF-Lact OF VACCINIA VIRUS, HAVING ONCOLYTIC ACTIVITY AND PRODUCING GRANULOCYTIC-MACROPHAGAL COLONY-STIMULATING FACTOR AND ONCOTOXIC LACTAPTIN PROTEIN Russian patent published in 2016 - IPC C12N7/01 C12N15/27 C12N15/12 

FIELD: biotechnology.

SUBSTANCE: invention relates to a recombinant strain of vaccinia virus (VV). Disclosed recombinant strain VV-GMCSF-Lact is constructed based on strain L-IVP vaccinia virus, containing a deletion of virus thymidine kinase gene fragments and growth factor, in areas which are built: gene of human granulocyte-macrophage colony-stimulating factor (GM-CSF), structure of which corresponds to DNA matrix RNA of human GM-CSF, in central part of virus thymidine kinase gene; and lactaptin gene coding fragment of human kappa casein 23-134 a.o., in left terminal area of viral genome. Human GM-CSF gene is expressed under control of natural promoter P7.5 k vaccinia virus and produces secreted form of biologically active human GM-CSF in cells of mammals. Lactaptin gene is expressed under control of synthetic promoter of vaccinia virus P7.5synth and produces oncotoxic recombinant lactaptin protein. Disclosed strain is deposited in State collection of agents of viral infections and rickettsial diseases of FBIS SSC VB “Vector” under number V-688.

EFFECT: described strain has high oncolytic activity on human breast cancer cell and can be used in biotechnology.

1 cl, 5 dwg, 4 ex